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In a previous study we reported that clonally expan-
ded T cell receptor b-chain rearrangements charac-
terized the T cell receptor usage in skin lesions of
psoriasis vulgaris and indicated antigen-speci®c T cell
selection. To assess the relevance of clonal T cell
expansion for disease progression, we now deter-
mined if select clonal T cell receptor rearrangements
persisted over time and were present in nonlesional
skin. Sequential biopsies were taken from psoriatic
skin lesions of two patients. V-D-J junctional regions
of T cell receptor b-chain variable region gene fam-
ilies 2, 3, 6, 13S1, and BV17 were cloned and
sequenced, as these particular BV gene families are
preferentially selected in psoriatic skin lesions. The
lesional T cell receptor rearrangements were com-
pared with the T cell receptor usage in nonlesional
skin and in blood. Several T cell receptor b-chain
rearrangements with high transcript frequency in the
®rst lesional biopsy were again found in sequential
lesional biopsies taken as much as 3 y later from
psoriasis relapses. Only T cell receptor b-chain
rearrangements with low transcript abundance
showed variability in that several clones appeared for
the ®rst time or disappeared. Although nonlesional
skin also exhibited a restricted T cell receptor usage
with clonal T cell receptor rearrangements, the T cell
receptor usage in lesional and nonlesional skin dif-
fered nearly completely. The select lesional recur-
rence of identical T cell receptor rearrangements
reveals that in¯ammation in psoriasis involves the
same clonally expanded T cell populations and the
same antigens over prolonged periods of time. It
hereby suggests that speci®cally recruited and locally
expanded T cell clones are permanently involved in
psoriatic in¯ammation and may play a crucial part
in disease perpetuation. Key words: clonal expansion/
psoriasis/T cell receptor rearrangements. J Invest Dermatol
117:1296±1301, 2001
P
soriasis vulgaris is a chronic in¯ammatory disease that
affects 1.5±2% of individuals in Western societies with
often severe and disabling in¯ammation of the skin and,
in a certain proportion of patients, arthritis. Skin lesions
are characterized by the distinctive combination of
highly increased keratinocyte proliferation with excessive scaling,
lesional accumulation of neutrophilic granulocytes, and a dense
mononuclear in®ltrate with activated T cells (Bos et al, 1983).
Although its pathogenesis has not been ®nally elucidated, psoriasis
bears many features of a T cell mediated autoimmune disease. It
shows a strong HLA association (Henseler, 1997). Psoriasis shares
predisposing genes with Crohn's disease, an autoimmune in¯am-
matory bowel disease (Nair et al, 1997), and with multiple sclerosis
(Becker et al, 1998). T cell-directed immunosuppression is an
effective handle for controlling disease activity (summarized in
Prinz, 1999). Only activated T cells from psoriasis patients but not
healthy controls induced psoriasis-like changes when injected into
human skin samples transplanted on to SCID mice (Wrone Smith
and Nickoloff, 1996). T cell clones established from psoriatic skin
lesions had the select capacity of enhancing the proliferation of
keratinocytes in vitro (Prinz et al, 1994; Bata-Csorgo et al, 1995),
and they produce a particular cytokine pattern that according to the
biologic activities of its individual cytokines should be able to
induce also the other features of psoriatic in¯ammation (Vollmer et
al, 1994).
These results prompted the need to clarify how the T cells
become activated within the skin of patients to initiate psoriatic
lesions. For this purpose various studies have analyzed the lesional
psoriatic T cell receptor (TCR) usage. Both the use of monoclonal
TCR b-chain variable region (TCRBV)-speci®c antibodies and
polymerase chain reaction (PCR)-based analysis of TCRBV gene
expression largely agreed on a preferential lesional enrichment of T
cells rearranging BV2 or BV6 TCR (Lewis et al, 1993; Leung et al,
1995; Menssen et al, 1995). Some authors considered this as an
indicator of superantigen-mediated T cell activation as molecular
analysis could not always identify clonal TCR rearrangements
within these two BV gene families (Leung et al, 1995; Vekony et al,
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1997; Davison et al, 1999). When lesional TCR analysis was
extended to other BV gene families such as BV3, BV8, BV9, BV12,
BV13S1 or BV17, however, repetitive TCR rearrangements were
usually detected and revealed the presence of oligoclonal T cell
populations (Chang et al, 1994; Menssen et al, 1995; Vekony et al,
1997; Bour et al, 1999; Prinz et al, 1999). These data suggested that
T cell activation in psoriatic in¯ammation is antigen speci®c.
Identi®cation of a conserved TCRB CDR3 motif within skin
lesions from different patients (Prinz et al, 1999) as well as of
identical TCR rearrangements in skin lesions and in synovia from
patients with psoriatic arthritis (Tassiulas et al, 1999) furthermore
suggested that a common psoriatic antigen may be driving
responses in different patients and in different tissues affected by
psoriasis.
Inasmuch as the putative psoriatic trigger remains unknown, data
on the TCR usage represent the main source of information on the
mode of lesional psoriatic T cell activation. In 1995 we published a
®rst analysis of the lesional TCR usage in psoriasis patients that
indicated oligoclonal T cell expansion (Menssen et al, 1995). To
determine whether these lesional T cell clones were truly disease
speci®c we analyzed the TCR usage in sequential lesional biopsies
and compared it with nonlesional skin and blood of the same
individuals. If the dominating lesional T cell clones should be of
any relevance for the disease, we should be able to ®nd at least some
of them constantly associated with affected areas but not in
nonlesional skin. Analysis of long-term variations of the lesional
TCR usage is furthermore required to clarify whether once
established the psoriatic immune response stably recognizes a
limited set of antigens or spreads to additional antigen determinants.
Experimental data on these issues are necessary to corroborate the
selective pathogenic role of T cells in the perpetuation of a skin
disease that for decades was regarded merely as a hyperproliferative
disturbance of keratinocyte homeostasis. Furthermore, they are
expected to shed some light on the existence and immunodomi-
nance of so far unidenti®ed autoantigens in psoriasis.
MATERIALS AND METHODS
Skin biopsies, blood lymphocytes, and preparation of RNA
Patients' consent and ethical approval were obtained prior to the study.
Spindle-shaped biopsies of approximately 2 cm length were obtained
from psoriatic skin lesions or nonlesional skin. A small piece of each
biopsy was subjected to histopathologic analysis. The remaining samples
were homogenized in GT buffer (4 M guanidinium isothiocyanate,
50 mM Tris±HCl, 10 mM ethylenediamine tetraacetic acid, 100 mM
b-mercaptoethanol) (Menssen et al, 1995). Paired blood samples were
taken simultaneously with the biopsies. Preparation of blood lymphocytes
and extraction of total cellular RNA were performed essentially as
described (Vollmer et al, 1994; Menssen et al, 1995).
PCR ampli®cation, cloning and sequencing of TCRB rearrange-
ments Ampli®cation of TCRB transcripts was performed as described
recently (Menssen et al, 1995; Prinz et al, 1999). In brief, TCRB-speci®c
cDNA templates were prepared by reverse transcription using an
oligonucleotide primer speci®c for the TCRB constant region mRNA:
5¢ TGTCCGAAGAAGGGGCTGGT 3¢. TCRB cDNA was ampli®ed
using a primer corresponding to a common sequence of both BC1 and
BC2 (3¢Cb-BglII: 5¢ GCCTTTTGGGTGTGGGAGATC) in combin-
ation with 5¢ BV primers containing different restriction endonuclease
sites:
5¢ BV2-HindIII: 5¢ TCATCAACCATGCAAGCTTGACCT 3¢;
5¢ BV3-PstI: 5¢ CCTGATTCTGCAGTCCGCCA 3¢;
5¢ BV6-BamHI: 5¢ AGGCCTGAGGGATCCGTCTC 3¢;
5¢ BV13S1-EcoRI: 5¢ CAGAGGAATTCCCGCTCAG 3¢;
5¢ BV17-Pstl: 5¢ GGA GAT ATA GCT GCA GGG TAC A 3¢:
To exclude the contamination of PCR probes, negative control
reactions without cDNA were set up with each primer pair and
ampli®ed for 40 PCR cycles. The digested TCRBV-BC PCR fragments,
including negative control reactions, were ligated into pUC19 vector
and used for Escherichia coli transformation. Plasmid DNA was sequenced
using an ABI Prism 310 genetic analyzer and the ABI BigDye terminator
cycle sequencing kit (Applied Biosystems, Warrington, U.K.) according
to the manufacturer's advice.
RESULTS
Approach Two psoriasis patients with severe chronic plaque
psoriasis, which in a former study had shown clonal alterations of
the lesional TCR repertoire (Menssen et al, 1995), were included in
this study. In both patients, we followed the lesional psoriatic TCR
usage over time in sequential biopsies, and we compared it with the
TCR usage in lesion-free skin and in blood. Whereas in our initial
study only TCRBV2 and BV6 gene families had been analyzed
(Menssen et al, 1995), TCR analysis was now extended to other BV
gene families (BV3, BV13S1, and BV17), which also may be
preferentially selected in psoriatic skin lesions as well as in normal
skin of healthy individuals (Chang et al, 1994; Menssen et al, 1995,
2000; Vekony et al, 1997; Prinz et al, 1999)
Patient H.K. (aged 54 y at the time of the ®rst biopsy) had a
disease duration of 36 y and patient H.W. (aged 55 y) of 19 y. In
patient H.K., three lesional biopsies from different sites (Table I)
and blood samples were taken at 18 mo intervals each. In this
patient preliminary data on BV6 TCR rearrangements in the
second lesional biopsy had provided ®rst evidence of lesionally
persisting TCR rearrangements (Menssen et al, 1995). In patient
H.W. two lesional biopsies (Table I) and blood samples were
obtained at 31 mo intervals. Between the biopsies, disease had been
treated to full remission, and it had relapsed prior to the next
biopsy, respectively. In both patients a biopsy from clinically
unaffected skin was taken simultaneously with the last lesional
biopsy. All biopsies were validated by dermatohistopathologic
analysis.
In each of the skin and blood samples cDNA of TCRBV2, 3, 6,
13S1, and BV17 gene families were ampli®ed by PCR. PCR
products spanned the V-D-J junctional region of the TCR b-chain,
respectively. This part encodes the hypervariable complementarity
determining region 3 (CDR3), which contributes to antigen
recognition by contacting the major histocompatibility complex±
peptide complex (Garboczi et al, 1996; Garcia et al, 1996). PCR
products were cloned and sequenced. Amino acid sequences were
deduced from the nucleotide sequence of the TCRB-V-D-J
rearrangements. Only functional in-frame TCR rearrangements
were utilized. The results are given as the number of identical
transcripts within the total number of sequenced rearrangements.
As a clone we de®ned those TCR rearrangements that were found
at least twice. These TCR rearrangements are given in Tables II
and III. In order to achieve meaningful results a total of over 1000
TCR b-chain rearrangements from skin and blood were analyzed.
TCRB rearrangements in psoriatic skin lesions, nonlesional
skin, and blood of patient H.K. Two prevailing TCRBV
rearrangements were detected in all three sequential lesional
biopsies of patient H.K. A particular TCRBV6 gene
rearrangement (clone HK 20) represented 19 of 33 (biopsy 1),
®ve of 25 (biopsy 2), or 21 of 24 (biopsy 3) of the analyzed
transcripts. A TCRBV13S1 gene rearrangement (HK25)
represented two of 19 (biopsy 1), four of 34 (biopsy 2), or eight
of 27 (biopsy 3) transcripts (Table II). Various other recurrent
TCRBV rearrangements were observed; however, they usually
occurred at low frequency, and none of them was detected in all
three sequential biopsies (Table II). Some were present only in
one of the three biopsies (clones HK1-3, 7, 8, 11±13, 28, 29, 32,
33, 37±40). Others were detected in two sequential biopsies, either
in biopsies 1 and 2 (clones HK 21, 27, 35), or 2 and 3 (clones HK 9,










H.K. Upper right back Right ¯ank Lower left ¯ank Right ¯ank
H.W. Right ¯ank Left ¯ank Not done Right ¯ank
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10, 36). Two TCR rearrangements were found in the ®rst and
third, but not in the second biopsy (clones HK 26, 34).
Repetitive TCR rearrangements were also observed in non-
lesional skin. Most prevailing were a BV3 and a BV6 TCR
rearrangement that represented 10 of 37 (HK14) or 10 of 18
(HK22) of the transcripts (Table II). TCR rearrangements from
lesional and nonlesional skin differed nearly completely. Only two
TCR rearrangements with low copy number in nonlesional skin
were also detected as single TCR transcripts within lesional skin at
the time of the third biopsy (HK4, HK30).
Simultaneously with the skin biopsies we also analyzed the BV2,
BV3, BV6, BV13S1, and BV17 gene families in the corresponding
blood samples. Only in the paired blood sample of biopsy 2, a
TCRBV rearrangement identical to the lesional TCRBV clone
HK20 was detected once among 20 BV6 transcripts. None of the
other BV gene rearrangements from lesional or nonlesional skin
was detected in blood lymphocytes (data not shown).
TCRB rearrangements in psoriatic skin lesions, nonlesional
skin, and blood of patient H.W. Various TCRBV
rearrangements were observed in both lesional biopsies of patient
H.W. (Table III). They belonged mainly to the BV3 or BV17
gene family. Some of these clones showed a high transcript
frequency (HW7, HW8, HW9, HW47, HW48) whereas others
had only low copy numbers (Table II). A particular TCRB
rearrangement, HW9, coded for the amino acid motif GQPT.
Most interestingly, biopsy 1 but not 2 revealed two other TCR that
were closely related to this CDR3 motif. Clone HW10 (two of 38)
coded for GQHT, and HW11 for GQAT (one of 38). The amino
acids GQ resulted from the BD1.1 gene segment, whereas the
other two amino acids (PT, AT, HT) resulted from N-region
diversi®cation, respectively. All three TCR rearrangements of
clones HW9-11 were rearranged to the BJ2S7 gene segment.
BJ2S7 was used by six of the eight clonally expanded TCRBV3
rearrangements.
Table II. TCR rearrangements and frequency in sequential lesional biopsies and nonlesional skin of patient H.K
BVa Clone BV NDNb BJ Biopsy 1c Biopsy 2 Biopsy 3
Lesion-free
skin
BV2S1 HK1 CSAR DSFSPRGd ETQYF BJ2S5 2/19 NDe ±f ±
HK2 CSA KERGS SYEQYF BJ2S7 2/19 ND ± ±
HK3 CSAR DEGKGM NSPLHF BJ1S6 ± ND 2/18 ±
HK4 CSA SRRGRS GYTF BJ1S2 ± ND 1/18 1/15
HK5 CSA LAGP TDTQYF BJ2S3 ± ND ± 3/15
HK6 CSA RGPWGT ETQYF BJ2S5 ± ND ± 3/15
BV3 HK7 CAS STRDRN QETQYFG BJ2S5 2/16 ± ± ±
HK8 CAS RTSGVVS SYNEQFFG BJ2S1 3/16 ± ± ±
HK9 CASSL GTA SYEQYFG BJ2S7 ± 1/27 1/30 ±
HK10 CASS SGRR QPQHFG BJ1S5 ± 1/27 1/30 ±
HK11 CAS RDSART QHFG BJ1S5 ± 2/27 ± ±
HK12 CAS TAATSGGQG EQFFG BJ2S1 ± ± 3/30 ±
HK13 CA TQDAA NEKLFFG BJ1S4 ± ± 3/30 ±
HK14 CASS FRPGQGA NQPQHFG BJ1S5 ± ± ± 10/37
HK15 CASS LLP TNEKLFFG BJ1S4 ± ± ± 7/37
HK16 CASSL FSG NQPQHFG BJ1S5 ± ± ± 5/37
HK17 CASS PLRDR AKNIQYFG BJ2S4 ± ± ± 5/37
HK18 CASS SIWDREG ETQYFG BJ2S5 ± ± ± 4/37
HK19 CASS TLGSTMG YEQYFG BJ2S7 ± ± ± 3/37
BV6
BV6S1 HK20 CASS GTAP NEQFF BJ2S1 19/33 5/25 21/24 ±
BV6S2 HK21 CASS SNLLGLG ETQYF BJ2S5 5/33 1/25 ± ±
BV6S5 HK22 CASS YGGTD EQYF BJ2S7 ± ± ± 10/18
BV6S1 HK23 CASS LGTR NEQFF BJ2S1 ± ± ± 2/18
BV6S6 HK24 CASS PTGGG ETQYF BJ2S5 ± ± ± 2/18
BV13S1 HK25 CASSY GRGQ SNQPQHFG BJ1S5 2/19 4/34 8/27 ±
HK26 CASSY QGGSLR ETQYFG BJ2S5 2/19 ± 2/27 ±
HK27 CAS SSNPDR SYEQYFG BJ2S7 1/19 1/34 ± ±
HK28 CASS YLLARG DTQYFG BJ2S3 ± 2/34 ± ±
HK29 CAS MAGGA YEQYFG BJ2S7 ± 2/34 ± ±
HK30 CASSY QPH YEQYFG BJ2S7 ± ± 1/27 2/17
HK31 CAS RQDRGQG TQYFG BJ2S5 ± ± ± 2/17
BV17 HK32 CASS IGGDG ETQYFG BJ2S5 3/23 ± ± ±
HK33 CASS MNR NQPQHFG BJ1S5 3/23 ± ± ±
HK34 CASS IGPGK NQPQHFG BJ1S5 2/23 ± 1/23 ±
HK35 CASS IQG TDTQYFG BJ2S3 2/23 1/18 ± ±
HK36 CASS SGGVI TEAFFG BJ1S1 ± 1/18 2/23 ±
HK37 C ATRDLD NYGYTFG BJ1S2 ± 4/18 ± ±
HK38 CASS RDS STDTQYFG BJ2S3 ± 3/18 ± ±
HK39 CASS ILLRSGESP YNEQF BJ2S3 ± ± 3/23 ±
HK40 CASS RTV NQPQHFG BJ1S5 ± ± 3/23 ±
aAmpli®ed TCR products were ligated into pUC19 vector and transformed in E. coli. cDNA of randomly picked clones was sequenced.
bCDR3 sequences are given as one letter amino acid code. The breaks in the sequences are used to distinguish by which gene segment the amino acids comprising the
CDR3s are encoded. CDR3 length was determined according to Rock et al (1994). Only functional rearrangements were utilized.
cFrequency gives the number of identical transcripts/total TCRB rearrangements analyzed for a particular BV gene family. Only repetitive TCR rearrangements are gi-
ven.
dUnderlined amino acids are BD encoded as de®ned by containing four or more continuous nucleotides of the D gene segment.
eND, not determined.
f±, not detected.
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Various other repetitive TCR transcripts were observed either in
the ®rst or in the second biopsy (Table III). They consisted mainly
of TCR rearrangements with low repetitive transcript frequency,
but also included two dominant TCR rearrangements. In biopsy 1,
a TCRBV2S1 rearrangement coding for the CDR3 motif GLAL
(HW1) represented six of 19 transcripts, and a BV6 transcript
coding for the CDR3 motif PGGG (HW21) nine of 18 transcripts.
Neither of them was detected in biopsy 2. The virtual absence of
clone HW21 (PGGG) in biopsy 2 was con®rmed by sequencing 59
TCRBV6 transcripts (which was a particularly high number), as
well as using PCR with a 5¢ oligonucleotide primer corresponding
to the PGGG motif. No speci®c fragment could be ampli®ed from
the cDNA of biopsy 2 (data not shown). Instead of the PGGG
motif, however, biopsy 2 contained a repetitive TCR clone coding
for a similar CDR3, PGGSGSL (HW25) that was rearranged to the
same BJ gene segment as HW21 (BJ2S1).
As in patient H.K., several repetitive TCR rearrangements with
high transcript frequency were observed in clinically unaffected skin
of patient H.W. They were totally disparate from those of lesional
skin (Table III). Furthermore, none of the BV gene rearrangements
of psoriatic skin lesions or nonlesional skin was detected in blood
lymphocytes drawn simultaneously (data not shown).
DISCUSSION
The clonal origin of T cells is re¯ected by their TCR rearrange-
ments that act as a ®ngerprint of an individual T cell. In
in¯ammatory in®ltrates repetitive TCR rearrangements are con-
Table III. TCR rearrangements and frequency in sequential lesional biopsies and nonlesional skin of patient H.W
BVa Clone BV NDNb BJ Biopsy 1c Biopsy 2
Lesion-free
skin
BV2S1 HW1 CSAR GLALd DTQYF BJ2S3 6/19 ±f ±
HW2 CSA SRDN TGELFF BJ2S2 3/19 ± ±
HW3 CSAR RGSA QETQYF BJ2S5 ± 3/13 ±
HW4 CSA WTSGVLI NEQFF BJ2S1 ± 3/13 ±
HW5 CSAR DPGQAD TGELFF BJ2S2 ± ± 9/15
HW6 CS ALVLSGL TDTQYF BJ2S3 ± ± 6/15
BV3 HW7 CAS SPRRGGTET YEQYFG BJ2S7 6/38 3/35 ±
HW8 CASS YRGLLQ GYTFG BJ1S2 4/38 14/35 ±
HW9 CASS GQPT YEQYFG BJ2S7 11/38 5/35 ±
HW10 CASS GQHT YEQYFG BJ2S7 2/38 ± ±
HW11 CASS GQAT YEQYFG BJ2S7 1/38 ± ±
HW12 CASS PSGTR TDTQYFG BJ2S3 1/38 1/35 ±
HW13 CAS ILGESET YEQYFG BJ2S7 1/38 1/35 ±
HW14 CAS RDS YEQYFG BJ2S7 2/38 ± ±
HW15 CAS RRGR ETQYFG BJ2S5 2/38 ± ±
HW16 CASS IAGD NYGYTFG BJ1S2 ± ± 12/29
HW17 CASS FSS YEQYFG BJ2S7 ± ± 6/29
HW18 CASS LLGD HSNQPQH BJ1S5 ± ± 6/29
HW19 CASS FKWTWHLF SGANVL BJ2S6 ± ± 2/29
HW20 CAS KWGRG ETQYFG BJ2S5 ± ± 2/29
BV6
BV6S2 HW21 CASS PGGG NEQFF BJ2S1 9/18 ± ±
BV6S2 HW22 CASS LYLAGGRH EQFF BJ2S1 2/18 ± ±
BV6S2 HW23 CASSL YSGI TGELFF BJ2S2 2/18 ± ±
BV6S1 HW24 CASSL VSTVLSK TNEKLF BJ1S4 ± 2/59 ±
BV6S1 HW25 CASS PGGSGSL FFG BJ2S1 ± 2/59 ±
BV6S2 HW26 CASSL GGV YEQYFG BJ2S7 ± 5/59 ±
BV6S5 HW27 CAS TYSAN TGELFFG BJ2S2 ± 2/59 ±
BV6S2 HW28 CASSL PGSE PQHFG BJ1S5 ± 3/59 ±
BV6S3 HW29 CASS LVAV STDTQYF BJ2S3 ± 3/59 ±
BV6S5 HW30 CASSL EGTSGR YEQYFG BJ2S7 ± ± 5/17
BV6S5 HW31 CASSL DRGA YGYTFG BJ1S2 2/17
BV6S2 HW32 CASSL RGF ETQYFG BJ2S5 2/17
BV13S1 HW33 cassy ggqgt qyfg BJ2S3 2/30 ± ±
HW34 CASS YSPGLAGVG EQYFG BJ2S7 2/30 ± ±
HW35 CASSY SGGY YNEQFFG BJ2S1 3/30 ± ±
HW36 cassy ssrga QFFG BJ2S1 2/30 ± ±
HW37 cassy etmiagr TGELFFG BJ2S2 2/30 ± ±
HW38 CASSY LEG YEQYFG BJ2S7 2/30 ± ±
HW39 CAS RTGTGS YGYTFG BJ1S2 3/30 1/23 ±
HW40 cass dhr tdtqyfg BJ2S3 3/30 ± ±
HW41 CASS SRQA NYGYTFG BJ1S2 2/30 ± ±
HW42 CASSY FGLG NEQFFG BJ2S1 ± 5/23 ±
HW43 CASS SRQPQ ETQYFG BJ2S5 ± 2/23 ±
HW44 CASSY LASS YGYTFG BJ2S1 ± ± 13/25
HW45 CAS RALAG QETQYFG BJ2S5 ± ± 5/25
HW46 CASSY TRQV TGELFFG BJ2S2 ± ± 6/25
BV17 HW47 CAS TRDGI EQFFG BJ2S1 10/26 1/22 ND
HW48 CASS IRGSSGTHAN TGELFFG BJ2S2 6/26 8/22 ND
HW49 CASS YEGV SYEQYFG BJ2S7 1/26 1/22 ND
HW50 CAS RQLQGP TDTQYFG BJ2S3 1/26 2/22 ND
HW51 CASS TRQDH YGYTFG BJ1S2 ± 2/26 ND
For key please refer to Table II.
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sidered to represent clonal T cell populations that have expanded in
response to antigen stimulation. Therefore, analysis of TCR
rearrangements at the sites of in¯ammatory tissue damage has
been employed to de®ne T cell activation pathways in various
immunologically mediated disorders (Marguerie et al, 1992). The
most striking result of this study was the identi®cation of TCR
clones that were repeatedly present in lesional psoriatic biopsies
obtained up to 3 y apart. Some of them were predominated by
transcript frequency and constituted up to 88% of a given TCRBV
gene family, whereas others were present in smaller copy numbers.
Three aspects add particular signi®cance to this ®nding. In the
period between the sequential lesional biopsies the disease had been
treated to full remission and had relapsed before the next biopsy.
Subsequent biopsies were taken from different sites. The dominant
lesional TCR clones were not detected in samples from clinically
unaffected skin, and they were usually absent from blood.
Therefore, these data suggest that the same clonal T cell
populations entered psoriatic skin lesions at distant sites over the
analyzed period of 3 y. The absence from nonlesional skin supports
the fact that the T cells bearing these TCR have not merely
persisted in the skin but that the preferential T cell recruitment and
clonal expansion was actually related to disease manifestation. The
select lesional recurrence of the same TCR rearrangements,
therefore, suggests that T cells bearing these clonal TCR
rearrangements are causally associated with the psoriatic in¯amma-
tion and play a crucial part in chronicity and perpetuation of
psoriasis.
In various T cell mediated disorders a lasting antigen-speci®c T
cell response to the dominant antigens is re¯ected by clonal TCR
rearrangements that selectively persist within the affected tissue.
The same dominant TCR rearrangements were repeatedly
observed in affected joints of rheumatoid arthritis (Alam et al,
1996) and of juvenile rheumatoid arthritis (Grom et al, 1993).
Multiple sclerosis was found to be characterized by stable T cell
responses against an immunodominant autoantigen, myelin basic
protein (Wucherpfennig et al, 1994). Based on the analysis of TCR
rearrangements, skin lesions of atopic eczema were observed to
harbor the same allergen-speci®c T cell clones for several years
(Bohle et al, 1998). The long-lasting, persistent TCR usage within
psoriasis patients, therefore, also proposes a predominant and stable
T cell response against a major psoriatic antigen.
Despite the long disease duration in both patients, the lesional
TCR repertoire still revealed dynamic changes in that several
lesional TCR clones disappeared, appeared for the ®rst time or
reappeared again. In particular the analysis of three subsequent
lesional biopsy in patient H.K. demonstrated that the emergence of
new TCR clones may only be transient as several TCR clones
were detected only in one or two of the three biopsies. In patient
H.W. we con®rmed that for one select clonal TCR rearrangement
(clone HW 21) the lack of detection in a subsequent biopsy may
actually represent true absence from the lesion: neither with an
increased number of sequenced transcripts nor by PCR ampli®-
cation using a 5¢ primer speci®c for the particular V-D-J
rearrangement could we identify clone-speci®c cDNA. Usually,
however, transiently present TCR rearrangements did not reach a
high transcript frequency. Therefore, we assume that these clones
are less likely to play a major part in disease progression. But also by
transient activation and expansion the corresponding T cells may
aggravate ongoing disease, as T cell heterogeneity seems to
correlate with disease severity (Utz et al, 1994).
Newly emerging T cell clones may indicate T cell recognition of
cryptic epitopes and re¯ect an extension of the immune response
and determinant spreading (Lehmann et al, 1992). According to our
results, however, many of these clones seemed to emerge only
transiently; therefore, it appears unlikely that epitope spreading
would contribute signi®cantly to disease progression in the stage of
chronic plaque psoriasis that we analyzed.
A particular clone, HW9, with the CDR3 motif GQPT in
patient H.W. recurred in the second biopsy whereas two other
TCR rearrangements with homologous CDR3 motifs, GQHT
(HW10) or GQAT (HW11) rearranged to the same BJ gene
segment as HW9, were not detected any more. This observation
was of particular interest as to the CDR3 homology and the
common BJ2S7 region gene all three TCR might recognize the
same major histocompatibility complex±peptide complex. Further-
more, a dominant clone from biopsy 1 of H.W. (HW21) that
coded for the CDR3 amino acid motif PGGG rearranged to BJ2S1
seemed to be substituted in biopsy 2 by a clone with a very similar
CDR3 (PGGSGSL) also rearranged to BJ2S1. Thus, our data
suggest that during disease progression the same immunodominant
lesional antigens may simultaneously or alternately stimulate diverse
T cell clones with homologous CDR3 motifs. Most interestingly,
the PGGG motif was also detected in another study on the lesional
psoriatic TCR usage (Chang et al, 1994).
TCR repertoires in lesional and nonlesional skin and blood
within the same individual were clearly distinct. The difference in
lesional and nonlesional psoriatic TCR usage appeared to be even
more pronounced than in Crohn's disease, which is the only other
T cell mediated disorder in which to our knowledge the TCR
usage in lesional and nonlesional tissue has been compared
(Gulwani Akolkar et al, 1996). As in psoriasis, oligoclonal TCR
rearrangements were largely con®ned to affected parts of the bowel,
but several of the lesionally expanded TCR rearrangements were
also detected in disease-free mucosa; however, this was at a much
lower frequency. For both diseases, these results corroborate the
particular, antigen-selected nature of the pathogenic T cell
response.
In a recent study we demonstrated that clonally expanded TCR
rearrangements are characteristic of the normal skin of healthy
individuals (Menssen et al 2000). They can already be detected in
childhood and may re¯ect the continuous challenge of skin by
environmental antigens and neo-antigens recognized during tumor
immunosurveillance. Therefore, it was not surprising that lesion-
free skin from psoriasis patients showed a marked degree of TCR
clonality. The number of T cells in the lesional psoriatic in®ltrate as
compared with nonlesional skin is much increased (Bos et al, 1983).
The clonal dominance of distinct lesional TCR rearrangements
within this much increased T cell number stresses further that T cell
selection in lesional skin results from recognition of particular
antigens.
In summary, our data clearly support that the TCR usage within
psoriatic skin lesions is highly restricted. It involves dominant TCR
rearrangements that seem to be constantly associated with psoriasis
in¯ammation. These conserved TCR rearrangements suggest that
the psoriatic T cell response is dominated by long-lasting clonally
expanded T cells that are speci®cally recruited and activated within
the skin of psoriasis patients due to recognition of (a) select psoriatic
antigen(s). These T cell clones may act as driver clones that
perpetuate the disease process and thereby facilitate the transient
activation of other T cells with lower af®nity for the same antigen
or that recognize other but usually cryptic autoantigens within the
context of in¯ammation (Sercarz, 2000). Our data therefore
strongly support the concept that psoriatic in¯ammation involves
an antigen-speci®c T cell response, and that it may be possible to
identify the antigens responsible for much of the in¯ammation in
psoriasis.
This work was supported by grants from the Deutsche Forschungsgemeinschaft
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